BCYC (Bicycle Therapeutics) Debt-to-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics Debt-to-Asset?

Bicycle Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $5.55 Mil. Bicycle Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $5.53 Mil. Bicycle Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $996.75 Mil. Bicycle Therapeutics's debt to asset for the quarter that ended in Sep. 2024 was 0.01.

Bicycle Therapeutics Debt-to-Asset Historical Data

The historical data trend for Bicycle Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicycle Therapeutics Debt-to-Asset Chart

Bicycle Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.10

0.09

0.11

0.08

Bicycle Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.07	0.08	0.08	0.04	0.01

Competitive Comparison of Bicycle Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Bicycle Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicycle Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's Debt-to-Asset falls into.

Bicycle Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bicycle Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.876	+	40.08)	/	595.344
	=	0.08

Bicycle Therapeutics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.554	+	5.533)	/	996.746
	=	0.01

Bicycle Therapeutics (NAS:BCYC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bicycle Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicycle Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

50BA:Germany

Address

Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS

Website

https://www.bicycletherapeutics.com

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Executives

Travis Alvin Thompson	officer: Chief Accounting Officer	C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS
Nigel Crockett	officer: Chief Business Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Alistair Milnes	officer: Chief Operating Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Kevin Lee	director, officer: Chief Executive Officer	C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Michael Skynner	officer: Chief Operating Officer	C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Nicholas Keen	officer: Chief Scientific Officer	C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Alethia Young	officer: Chief Financial Officer	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Lee Kalowski	officer: President and CFO	C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Santiago Arroyo	officer: Chief Development Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Dominic Smethurst	officer: Chief Medical Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Kate Bingham	director	1365 MAIN STREET, WALTHAM MA 02451
Jose-carlos Gutierrez-ramos	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Plc Glaxosmithkline	director, 10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098